Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

BioNTech SE - American Depositary Shares (NQ:BNTX)

92.14 -3.81 (-3.98%)
Streaming Delayed Price Updated: 11:18 AM EDT, Jun 1, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about BioNTech SE - American Depositary Shares

< Previous 1 2 3 4 5 6 7 8 9
...
72 73 Next >
News headline image
Pfizer and BioNTech Announce Topline Data Demonstrating Robust Immune Response With Their LP.8.1-Adapted COVID-19 Vaccine 2025-2026 Formula
From Pfizer Inc.
Via Business Wire
News headline image
Why BioNTech Stock Crushed the Market Today ↗
The company might be close to commercializing its most advanced pipeline program. 
Via The Motley Fool
News headline image
Guidewire Software, Samsara, Zumiez And Other Big Stocks Moving Higher On Friday ↗
 
Via Benzinga
Why Did BioNTech Stock Surge 10% Pre-Market Today? ↗
Via Stocktwits
Pfizer, BioNTech Get FDA Clearance For Updated Covid Vaccine In Senior Adults And Younger At-Risk Population ↗
Via Stocktwits
News headline image
Breaking Down BioNTech: 12 Analysts Share Their Views ↗
 
Via Benzinga
News headline image
Shots Fired! After RFK Jr.'s Senate Grilling, Will Pfizer, Moderna Survive The Battle In D.C.? ↗
It's unprecedented times for the Covid vaccine market, experts say. And Pfizer and Moderna remain under significant pressure. 
Via Investor's Business Daily
News headline image
BioNTech Surges 10% On Promising Test Results For Its Cancer Smart Bomb ↗
The company's DualityBio-partnered drug met the pre-specified bar for success in a pivotal study. 
Via Investor's Business Daily
News headline image
BioNTech Advances On Positive Phase 3 Breast Cancer Drug Data ↗
BioNTech and DualityBio reported Phase 3 success for trastuzumab pamirtecan in HER2 breast cancer, setting stage for regulatory submission in China. 
Via Benzinga
News headline image
Robert Kennedy Jr.'s Leadership Can Only Bring More 'Harm,' Says Top Ex-CDC Official: 'Undoing Of Vaccination' In Works ↗
Daskalakis resigned due to political interference in CDC, fears harm will come from new direction. CDC leaders also resign in protest. 
Via Benzinga
BioNTech Gets Price Target Bumps From BofA, Clear Street After Strong Q2, Oncology Pipeline Push ↗
Via Stocktwits
News headline image
Earnings Scheduled For August 4, 2025 ↗
 
Via Benzinga
News headline image
A Look Ahead: BioNTech's Earnings Forecast ↗
 
Via Benzinga
News headline image
Marvell Technology, eBay, And DexCom Are Among Top 10 Large Cap Losers Last Week (August 25-August 29): Are The Others In Your Portfolio? ↗
Marvell, Hormel, and Keurig Dr Pepper led weekly large-cap losers on weak guidance and analyst downgrades. 
Via Benzinga
News headline image
RFK Jr. Rescinds Emergency Authorizations For COVID-19 Vaccines ↗
FDA approves Pfizer, Moderna, and Novavax Covid vaccines for high-risk groups as emergency authorizations end and vaccines transition to full marketing. 
Via Benzinga
News headline image
RFK Jr. Makes Good On Promise To End Covid Vaccine Mandate. BioNTech Tumbles. ↗
Shares of one vaccine-maker are under pressure on Robert F. Kennedy Jr.'s move on Wednesday. 
Via Investor's Business Daily
News headline image
Pfizer and BioNTech’s COMIRNATY® Receives U.S. FDA Approval for Adults 65 and Older and Individuals Ages 5 through 64 at Increased Risk for Severe COVID-19
From Pfizer Inc.
Via Business Wire
News headline image
Pfizer and BioNTech’s COMIRNATY® Receives U.S. FDA Approval for Adults 65 and Older and Individuals Ages 5 through 64 at Increased Risk for Severe COVID-19
From BioNTech SE
Via GlobeNewswire
News headline image
Trump Administration Plans To Pull COVID-19 Vaccines Off Market 'Within Months' ↗
The Trump administration may remove COVID-19 vaccines from the U.S. market as RFK Jr.'s allies gain influence at HHS, with a new vaccine task force led by a known skeptic. 
Via Benzinga
Topics Government
News headline image
3 Reasons Pfizer's 7%-Yielding Dividend Is Getting Safer ↗
This big pharma company's juicy dividend is looking even more attractive. 
Via The Motley Fool
Topics Earnings
News headline image
CDC Shooting Linked To Suspect's COVID-19 Vaccine Beliefs, Former Staff Blame RFK Jr. Hostility Toward Agency ↗
CDC shooting tied to anti-vaccine beliefs sparks warnings from staff, as leaders clash over the future of mRNA vaccines and federal health policy. 
Via Benzinga
News headline image
Former Surgeon General Slams RFK Jr. Over mRNA Cuts, Says US 'Conceding To China,' 2 Million Lives At Risk ↗
Adams warns cutting funding for mRNA vaccine research will cost lives, derail medical progress, and give China an advantage. 
Via Benzinga
News headline image
These Analysts Revise Their Forecasts On BioNTech After Q2 Results ↗
 
Via Benzinga
News headline image
BioNTech Narrows Losses, Q2 Revenue Doubles As Vaccine Collaboration Drives Growth ↗
BioNTech beat Q2 estimates with higher COVID vaccine revenue and reaffirmed 2025 guidance. 
Via Benzinga
News headline image
BioNTech SE (NASDAQ:BNTX) Q2 2025 Earnings: Revenue Surges 68.5%, Losses Narrower Than Expected ↗
BioNTech Q2 2025 earnings beat revenue estimates with $255.99M, narrowing losses to -$1.57 EPS. Shares rose 2% pre-market as oncology pipeline advances. 
Via Chartmill
Topics Earnings
News headline image
BioNTech Announces Second Quarter 2025 Financial Results and Corporate Update
From BioNTech SE
Via GlobeNewswire
News headline image
Pfizer's Ascent Signals Broader Health Sector Resilience Amidst Innovation Wave
In a notable shift, shares of Pfizer (NYSE: PFE) have recently edged higher, reflecting a burgeoning strength within the broader health sector. This uptick signals a renewed investor confidence in the... 
Via MarketMinute
Topics Artificial Intelligence Economy Intellectual Property
News headline image
Moderna's Key Patent Win Overshadowed By Gloomy Outlook ↗
Moderna beat Q2 earnings and revenue estimates, narrowed its annual forecast, won a key patent case, and plans to cut 10% of its global workforce. 
Via Benzinga
Topics Intellectual Property
News headline image
Bristol Myers Cuts Earnings Outlook As Legacy Drugs Face Generic Erosion ↗
Bristol Myers beat Q2 sales expectations but cut its 2025 EPS forecast as strategic charges and legacy product declines weighed on earnings. 
Via Benzinga
News headline image
Where Will Pfizer (PFE) Be in 5 Years? ↗
The big drugmaker should be even bigger over the next five years despite facing a patent cliff. 
Via The Motley Fool
Topics Intellectual Property
< Previous 1 2 3 4 5 6 7 8 9
...
72 73 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.